Ocular Therapeutix (NASDAQ:OCUL) Insider Pravin Dugel Sells 20,056 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Pravin Dugel sold 20,056 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $8.28, for a total transaction of $166,063.68. Following the sale, the insider directly owned 3,013,022 shares of the company’s stock, valued at approximately $24,947,822.16. This represents a 0.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Pravin Dugel also recently made the following trade(s):

• On Thursday, February 12th, Pravin Dugel sold 124,882 shares of Ocular Therapeutix stock. The shares were sold at an average price of $9.04, for a total transaction of $1,128,933.28.

Ocular Therapeutix Stock Performance

Shares of NASDAQ:OCUL traded down $0.30 during midday trading on Thursday, hitting $9.21. The company’s stock had a trading volume of 3,683,063 shares, compared to its average volume of 6,953,924. The stock’s 50 day simple moving average is $10.45 and its 200 day simple moving average is $11.61. Ocular Therapeutix, Inc. has a fifty-two week low of $5.78 and a fifty-two week high of $16.44. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -6.36 and a beta of 0.90. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.32 and a current ratio of 15.39.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The firm had revenue of $13.25 million for the quarter, compared to analyst estimates of $16.13 million. During the same quarter last year, the firm posted ($0.29) EPS. The company’s revenue was down 22.4% on a year-over-year basis. As a group, research analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on OCUL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, January 22nd. HC Wainwright lifted their target price on Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Citigroup restated an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Chardan Capital reiterated a “buy” rating and issued a $21.00 price objective on shares of Ocular Therapeutix in a research report on Wednesday, February 18th. Finally, Needham & Company LLC decreased their price objective on Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Ocular Therapeutix currently has an average rating of “Moderate Buy” and an average target price of $23.78.

Institutional Investors Weigh In On Ocular Therapeutix

Large investors have recently modified their holdings of the stock. Millennium Management LLC boosted its stake in Ocular Therapeutix by 3,136.1% in the 3rd quarter. Millennium Management LLC now owns 3,855,706 shares of the biopharmaceutical company’s stock valued at $45,073,000 after buying an additional 3,736,560 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Ocular Therapeutix by 2,003.2% during the third quarter. Alliancebernstein L.P. now owns 3,424,439 shares of the biopharmaceutical company’s stock valued at $40,032,000 after acquiring an additional 3,261,619 shares during the period. Avoro Capital Advisors LLC boosted its stake in shares of Ocular Therapeutix by 38.5% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock valued at $119,822,000 after purchasing an additional 2,850,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Ocular Therapeutix by 26.3% in the 4th quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock worth $140,523,000 after purchasing an additional 2,411,953 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in Ocular Therapeutix by 106.5% during the fourth quarter. Janus Henderson Group PLC now owns 4,229,202 shares of the biopharmaceutical company’s stock worth $51,321,000 after buying an additional 2,180,702 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors.

Key Headlines Impacting Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Director Richard L. Lindstrom purchased 60,229 shares at an average $7.66 (a 32% increase in his stake), a sizable insider buy that signals management confidence and creates direct demand support. SEC Filing – Lindstrom Form 4
• Positive Sentiment: Ocular will present detailed SOL‑1 data at the Macula Society meeting and host investor events — upcoming clinical readouts and management commentary can materially move the stock if results or guidance are positive. SOL‑1 Presentation
• Neutral Sentiment: Market positioning and expectations: the company faces an upcoming earnings report and analysts remain mostly bullish (consensus “Moderate Buy” with a wide target spread), so results or guide will likely swing sentiment short term. MarketBeat Summary
• Neutral Sentiment: Smaller insider sale: Nadia Waheed sold 3,510 shares at ~$7.74 (~1.1% of her stake); a modest disposition that by itself is unlikely to change long‑term investor conviction. SEC Filing – Waheed Form 4
• Negative Sentiment: Clustered executive selling on Feb 23: several insiders (S. Nayak, J. Heier, P. Kaiser and P. Dugel) sold shares at ~ $8.28 per share — the largest being Pravin Dugel (20,056 shares). The coordinated sales increase supply and can weigh on sentiment, especially given the volume shortfall. SEC Filing – Dugel Form 4
• Negative Sentiment: Short interest jumped ~27.8% in February to ~14.7M shares (about 6.9% of float), raising the potential for further downward pressure as bearish bets accumulate; higher short interest can also increase volatility around catalysts.
• Negative Sentiment: Needham cut its price target to $18 (from $20) on Feb 20 — a downward revision from a sell‑side firm that may damp investor enthusiasm despite several other buy ratings remaining in place. Needham Price Target Cut

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.